Gun Violence Data Lacks Meaning
Gun violence data may appear startling, but they lack meaningful context. It would help to correlate the statistics with broader ...
Business as Usual for Medicaid Payer, Centene
Centene earns billions of dollars and then uses its profits to back the campaigns of the officials who oversee those ...
Cannabis Pushed for Pain Management
Opioid emergency room visits drop by nearly 8 percent and opioid prescriptions are modestly lower in states where marijuana is ...
Not All Plans are Traditional Health Insurances
Experts caution that the rush to buy coverage also presents an opportunity for people selling alternative products.
Maternal Risk Extends Beyond the Birth
Fifty-three percent of maternal deaths occurred well after women left the hospital, between seven days and a year after delivery.
Administrative Acts of Healthcare Crime
The FDA has asked the DOJ for support in issuing its first ever injunction against six vaping manufacturers.
Thinking About Viruses
Viruses are acting differently. It's clear the pandemic altered the virosphere in unknown ways, with consequences yet to emerge.
Social Determinants of Venture Capital
Venture capital firms are pouring lavish sums into environmental health. Will there be a return on investment?
One Mammogram too Many?
One key harm that researchers are concerned about, besides the possible extra cost, is the chance of a false-positive result.
How Clinically Significant is a Healthy Diet?
The system is based on several systematic reviews of studies regarding risk factors like smoking and health outcomes such as ...
Montana Says ‘No’ to Health Innovation
Montana is signaling it might step away from an innovative way of setting the prices its public employee health plan ...
Few Health Drivers in Rural Towns
The riders are seniors who don’t have access to transportation, especially in rural areas where public transit options are limited.
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read morePopular
-
Employer-Sponsored Insurance Is Breaking Down. Price Data Tells You Where It’s Happening First.
-
Drug Pricing Transparency in an Era of Political Polarization: What MedPricer’s Data Reveals About a Contested Policy Landscape
-
Chronic Care Toolbox
-
The Importance of Access Control in the Workplace
-
State Regulators and the Federal Data Gap: How MedPricer Fills What CMS Leaves Incomplete
